Attorney Docket No.: KUZ0029US.NP
Inventors: Shirai et al.
Serial No.: 10/575,562
Filing Date: April 12, 2006

Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

## Listing of the claims:

Claim 1 (currently amended): A pressure-sensitive adhesive composition for use as a percutaneous absorption preparation which comprises:

- (a) a drug one or more drugs, and
- (b) polyisoprene,
- (c) a styrene/isoprene/styrene copolymer, and
- (d) solid polyisobutylene, in a proportion of (15-50)/(25-50)/(30-50) (10-60)/(10-50)/(20-60) parts by weight relative to the total weight of (b), (c) and (d) and further contains a non-solid isobutylene polymer and a petroleum-resin type tackifier, characterized in that the amount of the non-solid isobutylene polymer is 5 to 25 parts by weight per 100 parts by weight of the sum of (b), (c) and (d), wherein the content of the petroleum resin type tackifier is in a proportion of 10-80 parts by weight relative to the total weight of (b), (c) and (d), thereby exhibiting a removal resistance to water.

Claim 2 (currently amended): The pressure-sensitive-adhesive composition percutaneous absorption preparation

Attorney Docket No.:

Inventors:

KUZ0029US.NP Shirai et al.

Serial No.:

10/575,562

Filing Date: Page 4

April 12, 2006

according to claim 1 claim 13, wherein the viscosity average molecular weight of the solid polyisobutylene is not less than 900,000 and the viscosity average molecular weight of the non-solid polyisobutylene is not more than 70,000.

Claims 3-7 (canceled)

Claim 8 (currently amended): The pressure-sensitive-adhesive composition percutaneous absorption preparation according to claim 1 claim 13, wherein the drug is one or more drugs comprise a skin irritant, an analgesic-antiinflammatory agent, an antifungal agent, a centrally acting drug, a diuretic agent, a hypotensor, a coronary vasodilator, an antitussive-expectorant agent, an anti-histaminic agent, an anxiolytic, a cardiotonic agent, a contraceptive, an adrenal hormone or and/or a local anesthetic.

Claim 9 (currently amended): The pressure-sensitive adhesive composition percutaneous absorption preparation according to claim 1 claim 13, wherein a liner of the pressure-sensitive adhesive composition percutaneous absorption preparation is a film, a sheet or a foil of polyethylene, polypropylene, a polyester selected from

Attorney Docket No.: KUZ0029US.NP
Inventors: Shirai et al.
Serial No.: 10/575,562
Filing Date: April 12, 2006

Page 5

absorption preparation is a film, a sheet or a foil of polyethylene, polypropylene, a polyester selected from polyethylene terephthalate (PET) or polyethylene napthalate, nylon, aluminium, or paper, or a laminate material thereof.

Claim 10 (currently amended): The pressure-sensitive adhesive composition percutaneous absorption preparation according to claim 8 claim 13, wherein the drug is one or more drugs further comprises methyl salicylate, L-menthol and/or dl-camphor.

Claim 11 (new): The percutaneous absorption preparation according to claim 13, wherein the one or more drugs comprise a skin irritant, an analgesic-antiinflammatory agent, a centrally acting drug, a hypotensor, a coronary vasodilator, an antitussive-expectorant agent, an anti-histaminic agent, an anxiolytic, a cardiotonic agent, a contraceptive, an adrenal hormone and/or a local anesthetic.

Claim 12 (new): The percutaneous absorption preparation according to claim 1 wherein the tackifier is petroleum resin and the petroleum resins as the tackifier is in a proportion of 10-80 parts by weight relative to the total weight of (b), (c) and (d).

Attorney Docket No.: KUZ0029US.NP
Inventors: Shirai et al.
Serial No.: 10/575,562
Filing Date: April 12, 2006
Page 6

Claim 13 (new): The percutaneous absorption preparation according to claim 12, which comprises (b), (c) and (d) in a proportion of (15-50)/(25-45)/(30-50) parts by weight relative to the total weight of (b), (c) and (d).

Claim 14 (new): The percutaneous absorption preparation according to claim 1, which has a tackiness of a probe tack value in the range of 20-150 gf and a 180° removal in the range of 20-200 gf.

Claim 15 (new): The percutaneous absorption preparation according to claim 1, which reduces irritation to skin.

Claim 16 (new): The percutaneous absorption preparation according to claim 14, which reduces irritation to skin.

Claim 17 (new): A method for obtaining in a percutaneous absorption preparation applied to skin a tackiness of a probe tack value in the range of 20-150 gf and a 180° removal in the range of 20-200 gf, thereby exhibiting removal resistance in water while reducing skin irritation, said method comprising administering to the skin the percutaneous absorption preparation of claim 1.